NuVasive, Inc. (NASDAQ:NUVA) Files An 8-K Results of Operations and Financial Condition
Item 2.02
Results of Operations and Financial Condition.
On January7, 2019, NuVasive, Inc. issued a press release announcing preliminary unaudited revenue results for the fourth quarter and fiscal year ended December31, 2018. A copy of this press release is furnished as Exhibit 99.1 hereto.
The information contained in this Current Report and the Exhibit hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
NUVASIVE INC Exhibit
EX-99.1 2 nuva-ex991_49.htm EX-99.1 nuva-ex991_49.htm Exhibit 99.1 NEWS RELEASE NUVASIVE ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2018 REVENUE RESULTS SAN DIEGO – January 7,…
To view the full exhibit click here
About NuVasive, Inc. (NASDAQ:NUVA)
Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.
